{"title":"CD133在乳腺癌细胞和乳腺癌干细胞中作为免疫治疗的另一个靶点","authors":"Luis Tume , Karen Paco , Roberto Ubidia-Incio , Jeel Moya","doi":"10.1016/j.gamo.2016.01.003","DOIUrl":null,"url":null,"abstract":"<div><p>Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome.</p></div>","PeriodicalId":41581,"journal":{"name":"Gaceta Mexicana de Oncologia","volume":"15 1","pages":"Pages 22-30"},"PeriodicalIF":0.1000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gamo.2016.01.003","citationCount":"21","resultStr":"{\"title\":\"CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy\",\"authors\":\"Luis Tume , Karen Paco , Roberto Ubidia-Incio , Jeel Moya\",\"doi\":\"10.1016/j.gamo.2016.01.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome.</p></div>\",\"PeriodicalId\":41581,\"journal\":{\"name\":\"Gaceta Mexicana de Oncologia\",\"volume\":\"15 1\",\"pages\":\"Pages 22-30\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.gamo.2016.01.003\",\"citationCount\":\"21\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gaceta Mexicana de Oncologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1665920116000250\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gaceta Mexicana de Oncologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665920116000250","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy
Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
